These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35815550)

  • 21. Predictive Value of Hepatorenal Status in Contrast-Induced Nephropathy Among Patients Receiving Coronary Angiography and/or Intervention: A Systematic Review and Meta-Analysis.
    Zhang E; Lu Y; Chen G; Huang L; Zhang J; Wang C; Qin Q
    Angiology; 2019 Aug; 70(7):633-641. PubMed ID: 30525915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The predictive value of the renal resistive index for contrast-induced nephropathy in patients with acute coronary syndrome.
    Xu ZR; Chen J; Liu YH; Liu Y; Tan N
    BMC Cardiovasc Disord; 2019 Feb; 19(1):36. PubMed ID: 30744553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between elevated CHA2DS2-VASC score and contrast-induced nephropathy among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Del Rio-Pertuz G; Leelaviwat N; Mekraksakit P; Benjanuwattra J; Nugent K; Ansari MM
    Acta Cardiol; 2023 Oct; 78(8):922-929. PubMed ID: 37171278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inverse correlation between left ventricular end-diastolic pressure and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.
    Gu G; Xing H; Zhou Y; Cui W
    Clin Exp Nephrol; 2018 Aug; 22(4):808-814. PubMed ID: 29196838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of body habitus on contrast-induced acute kidney injury after percutaneous coronary intervention.
    Kuno T; Numasawa Y; Sawano M; Katsuki T; Kodaira M; Ueda I; Suzuki M; Noma S; Negishi K; Ishikawa S; Miyata H; Fukuda K; Kohsaka S
    PLoS One; 2018; 13(9):e0203352. PubMed ID: 30212493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic immune-inflammation index associated with contrast-induced nephropathy after elective percutaneous coronary intervention in a case-control study.
    Ma X; Mo C; Li Y; Gui C
    Coron Artery Dis; 2023 Sep; 34(6):432-440. PubMed ID: 37222216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of the blood urea nitrogen-to-left ventricular ejection fraction ratio with contrast-induced nephropathy in patients with acute coronary syndrome who underwent percutaneous coronary intervention.
    Kiris T; Avci E; Celik A
    Int Urol Nephrol; 2019 Mar; 51(3):475-481. PubMed ID: 30604231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between N-terminal pro-brain natriuretic peptide levels and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
    Kurtul A; Duran M; Yarlioglues M; Murat SN; Demircelik MB; Ergun G; Acikgoz SK; Sensoy B; Cetin M; Ornek E
    Clin Cardiol; 2014 Aug; 37(8):485-92. PubMed ID: 24805995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of contrast-induced nephropathy in chronic total occlusion percutaneous coronary intervention.
    Lin YS; Fang HY; Hussein H; Fang CY; Chen YL; Hsueh SK; Cheng CI; Yang CH; Chen CJ; Hang CL; Yip HK; Wu CJ
    EuroIntervention; 2014 Feb; 9(10):1173-80. PubMed ID: 24561734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors of contrast-induced nephropathy after percutaneous coronary intervention: a retrospective analysis.
    Wang J; Zhang C; Liu Z; Bai Y
    J Int Med Res; 2021 Apr; 49(4):3000605211005972. PubMed ID: 33878914
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
    Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
    Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography.
    Kanbay M; Siriopol D; Ozdogan E; Afsar B; Ertuglu LA; Grigore M; Sag AA; Kuwabara M; Lanaspa MA; Ortiz A; Johnson RJ; Covic A
    Int Urol Nephrol; 2020 Mar; 52(3):541-547. PubMed ID: 32008199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remote Ischemic Preconditioning Reduces the Risk of Contrast-Induced Nephropathy in Patients with Moderate Renal Impairment Undergoing Percutaneous Coronary Angiography: A Meta-Analysis.
    Deng J; Lu Y; Ou J; Shao X; Wang X; Xie H
    Kidney Blood Press Res; 2020; 45(4):549-564. PubMed ID: 32688358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of intravenous hydration on risk of contrast induced nephropathy and in-hospital mortality in STEMI patients undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.
    Liu Y; Hong D; Wang AY; Guo R; Smyth B; Liu J; Sun G; Chen S; Tan N; Jardine M; Brieger D; Shaman A; Islam S; Chen J; Gallagher M
    BMC Cardiovasc Disord; 2019 Apr; 19(1):87. PubMed ID: 30961544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
    Barbieri L; Verdoia M; Suryapranata H; De Luca G;
    Int J Cardiol; 2019 Jan; 275():48-52. PubMed ID: 30274753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention.
    Laskey WK; Jenkins C; Selzer F; Marroquin OC; Wilensky RL; Glaser R; Cohen HA; Holmes DR;
    J Am Coll Cardiol; 2007 Aug; 50(7):584-90. PubMed ID: 17692741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive Value of N-Terminal Pro B-Type Natriuretic Peptide for Contrast-Induced Nephropathy Non-Recovery and Poor Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.
    Luo M; Zhu Z; Zhang L; Zhang S; You Z; Chen H; Rao J; Lin K; Guo Y
    Circ J; 2023 Jan; 87(2):258-265. PubMed ID: 36288935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Transient or Persistent Contrast-induced Nephropathy on Long-term Mortality After Elective Percutaneous Coronary Intervention.
    Abe M; Morimoto T; Nakagawa Y; Furukawa Y; Ono K; Kato T; Kadota K; Ando K; Ishii M; Masunaga N; Akao M; Kimura T
    Am J Cardiol; 2017 Dec; 120(12):2146-2153. PubMed ID: 29106836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel risk assessment model of contrast-induced nephropathy after percutaneous coronary intervention in patients with diabetes.
    Yao ZF; Shen H; Tang MN; Yan Y; Ge JB
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):305-314. PubMed ID: 32991776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.